Raymond James & Associates Acquires 129,472 Shares of Sanofi (NASDAQ:SNY)

Raymond James & Associates grew its stake in shares of Sanofi (NASDAQ:SNY) by 4.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,819,348 shares of the company’s stock after acquiring an additional 129,472 shares during the quarter. Raymond James & Associates’ holdings in Sanofi were worth $162,479,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the stock. Blue Trust Inc. lifted its stake in shares of Sanofi by 31.7% in the 3rd quarter. Blue Trust Inc. now owns 18,046 shares of the company’s stock worth $1,040,000 after purchasing an additional 4,346 shares during the period. Net Worth Advisory Group bought a new stake in Sanofi during the 3rd quarter worth approximately $297,000. Aaron Wealth Advisors LLC boosted its position in shares of Sanofi by 13.7% in the third quarter. Aaron Wealth Advisors LLC now owns 22,239 shares of the company’s stock worth $1,282,000 after purchasing an additional 2,683 shares during the period. Stonegate Investment Group LLC increased its stake in shares of Sanofi by 62.8% in the third quarter. Stonegate Investment Group LLC now owns 8,751 shares of the company’s stock worth $504,000 after purchasing an additional 3,377 shares in the last quarter. Finally, Cardinal Capital Management increased its stake in Sanofi by 1.4% in the 3rd quarter. Cardinal Capital Management now owns 67,523 shares of the company’s stock worth $3,891,000 after buying an additional 938 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Up 0.1 %

NASDAQ:SNY opened at $54.93 on Friday. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market cap of $139.12 billion, a PE ratio of 27.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.60. The company has a 50-day moving average of $56.11 and a 200 day moving average of $51.55.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.95 EPS. As a group, research analysts anticipate that Sanofi will post 4.26 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Argus upped their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.